Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 1/20 | 0.55 |
| ▸ | DAO | P14920 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | DDO | Q99489 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 5/20 | 0.50 |
| ▸ | MMP13 | P45452 | 5/20 | 0.50 |
| ▸ | MMP9 | P14780 | 4/20 | 0.50 |
| ▸ | MMP8 | P22894 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | APAF1 | O14727 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | GALK1 | P51570 | 1/20 | 0.49 |
| ▸ | UBE2I | P63279 | 1/20 | 0.49 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16627659 | 0.87 | BRD4 (0.58) | PYGMDAOBRD4DDOMMP2 | |
| SCHEMBL16627647 | 0.87 | DAO (0.54) | PYGMDAOBRD4DDOMMP2 | |
| SCHEMBL16627640 | 0.86 | BRD4 (0.45) | PYGMDAOBRD4DDOMMP2 | |
| SCHEMBL16627631 | 0.84 | BRD4 (0.43) | PYGMDAOBRD4DDOMMP2 | |
| SCHEMBL16627633 | 0.84 | BRD4 (0.46) | PYGMDAOBRD4DDOMAPT | |
| SCHEMBL16627634 | 0.84 | DAO (0.46) | PYGMDAOBRD4DDOMMP2 | |
| SCHEMBL16627660 | 0.82 | HPGD (0.50) | BRD4MAPTKDM4EHPGDNPC1 | |
| SCHEMBL16627731 | 0.82 | BRD4 (0.55) | DAOBRD4DDOMMP2MMP13 | |
| SCHEMBL16627732 | 0.82 | DAO (0.55) | PYGMDAOBRD4DDOMAPT | |
| SCHEMBL7807599 | 0.80 | MMP2 (0.58) | PYGMMMP2MMP13MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190117683-A1 | ALGINATE OLIGOMERS FOR THE TREATMENT OR PREVENTION OF MICROBIAL OVERGROWTH IN THE INTESTINAL TRACT | ALGIPHARMA AS (NO) | 2019-04-25 | — | — | US | claimed |
| US-20180055873-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-03-01 | — | — | US | claimed |
| EP-3273995-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-01-31 | — | — | EP | claimed |
| WO-2017060388-A1 | ALGINATE OLIGOMERS FOR THE TREATMENT OR PREVENTION OF MICROBIAL OVERGROWTH IN THE INTESTINAL TRACT | ALGIPHARMA AS (NO) | 2017-04-13 | — | — | WO | claimed |
| WO-2016151051-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2016-09-29 | — | — | WO | claimed |
| CN-111867634-B | Enhancement of translocation of micro/nanoparticles across mucus layers using alginate oligomers | 阿尔吉法玛公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-3896063-B1 | CRYSTALLINE FORMS OF THE SYK INHIBITOR 5-FLUORO-1-METHYL-3-[[5-[4-(3-OXETANYL)-1-PIPERAZINYL]-2-PYRIDINYL]AMINO]-6-(1H-PYRAZOL-3-YL)-2(1H)-QUINOLINONE HYDROCHLORIDE SALT (1:1) | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2024-01-24 | — | — | EP | disclosed |
| EP-3273995-B1 | COMBINED USE OF ALGINATE OLIGOMERS AND THE CFTR MODULATOR LUMACAFTOR IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2021-07-14 | — | — | EP | disclosed |
| US-20210030891-A1 | USE OF ALGINATE OLIGOMERS TO ENHANCE THE TRANSLOCATION OF MICRO/NANOPARTICLES ACROSS MUCUS LAYERS | ALGIPHARMA AS (NO) | 2021-02-04 | — | — | US | disclosed |
| EP-3768323-A1 | USE OF ALGINATE OLIGOMERS TO ENHANCE THE TRANSLOCATION OF MICRO/NANOPARTICLES ACROSS MUCUS LAYERS | ALGIPHARMA AS (NO) | 2021-01-27 | — | — | EP | disclosed |
| US-10751363-B2 | Use of aliginate oligomers and CFTR modulators in treatment of conditions associated with CFTR dysfunction | ALGIPHARMA AS (NO) | 2020-08-25 | — | — | US | disclosed |
| WO-2019180047-A1 | USE OF ALGINATE OLIGOMERS TO ENHANCE THE TRANSLOCATION OF MICRO/NANOPARTICLES ACROSS MUCUS LAYERS | ALGIPHARMA AS (NO) | 2019-09-26 | — | — | WO | disclosed |
| US-20180055873-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-03-01 | — | — | US | disclosed |
| EP-3273995-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-01-31 | — | — | EP | disclosed |
| WO-2016151051-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2016-09-29 | — | — | WO | disclosed |
| WO-2015050379-A1 | NOVEL QUINOLINONE DERIVATIVE AND USE THEREOF | 광주과학기술원 | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030891-A1 | USE OF ALGINATE OLIGOMERS TO ENHANCE THE TRANSLOCATION OF MICRO/NANOPARTICLES ACROSS MUCUS LAYERS | MUC1, ALG1, ST3GAL3 | PYGM 3849/4885DAO 3029/4885BRD4 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.